Osteoclast-mediated bone loss observed in a COVID-19 mouse model

dc.contributor.authorAwosanya, Olatundun D.
dc.contributor.authorDalloul, Christopher E.
dc.contributor.authorBlosser, Rachel J.
dc.contributor.authorDadwal, Ushashi C.
dc.contributor.authorCarozza, Mariel
dc.contributor.authorBoschen, Karen
dc.contributor.authorKlemsz, Michael J.
dc.contributor.authorJohnston, Nancy A.
dc.contributor.authorBruzzaniti, Angela
dc.contributor.authorRobinson, Christopher M.
dc.contributor.authorSrour, Edward F.
dc.contributor.authorKacena, Melissa A.
dc.date.accessioned2024-04-26T17:21:00Z
dc.date.available2024-04-26T17:21:00Z
dc.date.issued2021-10-02
dc.description.abstractThe consequences of SARS-CoV-2 infection on the musculoskeletal system represent a dangerous knowledge gap. Aging patients are at added risk for SARS-CoV-2 infection; therefore, a greater understanding of the resulting musculoskeletal sequelae of SARS-CoV-2 infection may help guide clinical strategies. This study examined fundamental bone parameters among mice treated with escalating viral loads. Male C57BL/6J (WT, n = 17) and B6.Cg-Tg(K18-ACE2)2Prlmn/J mice (K18-hACE2 transgenic mice, n = 21) expressing human ACE2 (TG) were divided into eight groups (n = 4-6/group) and subjected to intranasal dosing of 0, 1 × 103, 1 × 104, and 1 × 105 PFU (plaque forming units) of human SARS-CoV-2. Animal health was assessed daily by veterinary staff using established and validated scoring criteria (activity, posture, body condition scores and body weight). We report here that mock and WT infected mice were healthy and completed the study, surviving until 12-14 days post infection (dpi). In contrast, the TG mice infected with 1 × 105 PFU all experienced severe health declines that necessitated early euthanasia (6-7 dpi). For TG mice infected with 1 × 104 PFU, 2 mice were also euthanized after 7 dpi, while 3 mice showed signs of moderate disease at day 6 dpi, but recovered fully by day 11 dpi. Four of the 5 TG mice that were infected with 1 × 103 PFU remained healthy throughout the study. This suggests that our study mimics what is seen during human disease, where some patients develop severe disease resulting in death, while others have moderate to severe disease but recover, and others are asymptomatic. At necropsy, femurs were extracted and analyzed by μCT. No difference was found in μCT determined bone parameters among the WT groups. There was, however, a significant 24.4% decrease in trabecular bone volume fraction (p = 0.0009), 19.0% decrease in trabecular number (p = 0.004), 6.2% decrease in trabecular thickness (p = 0.04), and a 9.8% increase in trabecular separation (p = 0.04) among surviving TG mice receiving any viral load compared to non-infected controls. No differences in cortical bone parameters were detected. TRAP staining revealed surviving infected mice had a significant 64% increase in osteoclast number, a 27% increase in osteoclast surface, and a 38% increase in osteoclasts per bone surface. While more studies are needed to investigate the long-term consequences of SARS-CoV-2 infection on skeletal health, this study demonstrates a significant reduction in several bone parameters and corresponding robust increases in osteoclast number observed within 2 weeks post-infection in surviving asymptomatic and moderately affected mice.
dc.description.sponsorshipThis project was supported, in part, by the Cooperative Center of Excellence in Hematology (CCEH) Award, funded in part by NIH 1U54DK106846 (MAK, EFS, UCD); the Indiana Clinical and Translational Sciences Institute, funded in part by NIH UL1TR002529 (MAK), NIH T32 DK007519 (UCD), NIH T32 AR065971 (UCD), and NIH T32 HL007910 (ODA). In addition, the results of this work were supported with resources and the use of facilities at the Richard L. Roudebush VA Medical Center, Indianapolis, IN: VA Merit #BX003751 (MAK).
dc.identifier.citationAwosanya OD, Dalloul CE, Blosser RJ, Dadwal UC, Carozza M, Boschen K, Klemsz MJ, Johnston NA, Bruzzaniti A, Robinson CM, Srour EF, Kacena MA. Osteoclast-mediated bone loss observed in a COVID-19 mouse model. Bone. 2022 Jan;154:116227. doi: 10.1016/j.bone.2021.116227. Epub 2021 Oct 2. PMID: 34607050; PMCID: PMC8486589.
dc.identifier.urihttps://hdl.handle.net/1805/40286
dc.relation.isversionof10.1016/j.bone.2021.116227
dc.subjectCOVID-19
dc.subjectInbred C57BL Mice
dc.subjectTransgenic Mice
dc.subjectOsteoclasts
dc.subjectSARS-CoV-2
dc.titleOsteoclast-mediated bone loss observed in a COVID-19 mouse model
dc.typeArticle
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Awosanya.pdf
Size:
2.07 MB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description: